Postmastectomy Radiation in HER-2 Positive Breast Cancer after Neoadjuvant Therapy: Secondary Analysis of Two Randomized Trials

被引：0
|
作者：
Zeidan, Y. [1 ]
Saifi, O. [2 ]
Bachir, B. [3 ]
Panoff, J. E. [4 ]
Poortmans, P. [5 ]
机构：
[1] Lynn Canc Inst, Baptist Hlth South Florida, Boca Raton, FL USA
[2] Mayo Clin, Dept Radiat Oncol, Jacksonville, FL USA
[3] Amer Univ, Beirut Med Ctr, Beirut, Lebanon
[4] Baptist Hlth South Florida, Miami Canc Inst, Dept Radiat Oncol, Miami, FL USA
[5] lridium Kankernetwerk, Dept Radiat Oncol, Antwerp, Belgium
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2461
引用
收藏
页码：E216 / E216
页数：1
相关论文
共 50 条
  • [31] ADJUVANT TRASTUZUMAB THERAPY IN HER2-POSITIVE BREAST CANCER PATIENTS: A META-ANALYSIS OF PUBLISHED RANDOMIZED TRIALS
    Xia, Y.
    Bian, B.
    Costea, E.
    Kelton, C. M.
    Guo, J. J.
    VALUE IN HEALTH, 2013, 16 (03) : A128 - A128
  • [32] The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer
    Nakashoji, Ayako
    Hayashida, Tetsu
    Yokoe, Takamichi
    Maeda, Hinako
    Toyota, Tomoka
    Kikuchi, Masayuki
    Watanuki, Rurina
    Nagayama, Aiko
    Seki, Tomoko
    Takahashi, Maiko
    Abe, Takayuki
    Kitagawa, Yuko
    CANCER TREATMENT REVIEWS, 2018, 62 : 9 - 17
  • [33] HER-2 positive inflammatory breast cancer: high pathological response rate with trastuzumab-based neoadjuvant therapy.
    Dawood, S.
    Gonzales-Angulo, A. M.
    Broglio, k
    Gong, Y.
    Resetkova, E.
    Yang, W. T.
    Barnett, C. M.
    Islam, R.
    Ueno, N. T.
    Hortobagyi, G. N.
    Cristofanilli, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S186 - S186
  • [34] Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer
    Guarneri, Valentina
    Barbieri, Elena
    Piacentini, Federico
    Dieci, Maria Vittoria
    Omarini, Claudia
    Ficarra, Guido
    Bettelli, Stefania Raffaella
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
    Dent, Susan
    Oyan, Basak
    Honig, Amd
    Mano, Max
    Howell, Sacha
    CANCER TREATMENT REVIEWS, 2013, 39 (06) : 622 - 631
  • [36] Clinicopathological characteristics of breast cancer patients with HER-2 low expression received neoadjuvant therapy
    Zhang, Shiyuan
    Yu, Xiao
    Xiu, Yuting
    Qiao, Kun
    Jiang, Cong
    Huang, Yuanxi
    ONCOLOGY, 2024, 102 (02) : 122 - 130
  • [37] Derivation and analysis of preclinical models of human her-2 positive breast cancer
    Valenzuela, Paloma A.
    Jallad, Sarah N.
    Parra, Karla
    Lerma, Natzidielly
    Miramontes, Irving
    Gallegos, Alejandra
    Xu, Ping
    Cruz-Munoz, William
    Man, Shan
    Kerbel, Robert S.
    Francia, Giulio
    CANCER RESEARCH, 2014, 74 (19)
  • [38] HER2-low-positive breast cancer from four neoadjuvant clinical trials
    Omar, Abeid
    Arafat, Waleed
    LANCET ONCOLOGY, 2021, 22 (10): : E426 - E426
  • [39] HER2 POSITIVE BREAST CANCER: LESSONS LEARNT FROM RECENT NEOADJUVANT TRIALS
    Piccart, M.
    Saini, K.
    Loi, S.
    Azim, H. A., Jr.
    Metzger-Filho, O.
    Capelan, M.
    Bozovic, I.
    De Azambuja, E.
    ANNALS OF ONCOLOGY, 2011, 22 : 24 - 25
  • [40] Pathologic tumor response & long term outcome with neoadjuvant trastuzumab in Her-2 positive breast cancer
    Zeeshan, S.
    Khan, S. M.
    Khan, N.
    ANNALS OF ONCOLOGY, 2016, 27
12345